SecBot SecBot

SRPT

Sarepta Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000873303 Biotech & Drug Discovery
$15.13 −0.94 (−5.85%)
Nov 16 4:00 PM ET · prev $16.07
Market cap
$1.7B
Small cap
Consensus
Hold
39% Buy or better · 31 analysts
Median target
$20.00
+32% · range $5.00–38.00
1 year
−13.7%
from $17.54 · Nov 17
30 days
−14.7%
from $17.73
52-week range
$14.86–23.83
−37% from high · low Jul 31
Avg volume 20D
1.86M
shares / day
Short interest
19.30M
≈18.0% of shares · −13.6%
Days to cover
7.8
at average volume
Insider net
−$123.2K
0 buyers · 1 seller · 12 mo
New fund stakes
1
Q2 2026 13F · 3 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 0 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 2/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $123.2K.

  • InstitutionsMIXED

    Q2 2026: 35 added (1 new), 38 trimmed or exited. Largest new: Qube Research & Technologies $11.0M.

  • AnalystsMIXED

    12 of 31 rate it Buy or better. Median target $20.00 (+32%).

  • Short sellersSTEADY

    Short interest −13.6% to 19.30M shares. 7.8 days to cover, ≈18.0% of shares.

  • TrendDOWNTREND

    18% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 26.

Who's buying

13F· Q2 2026
1
new positions
3
exits
$11.0M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD18,994,958$341.3M
STATE STREET CORPADD8,916,090$160.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD8,377,470$150.5M
GEODE CAPITAL MANAGEMENT, LLCADD2,771,758$49.8M
MARSHALL WACE, LLPDOUBLED2,206,022$39.6M
GOLDMAN SACHS GROUP INCADD2,042,501$36.7M
UBS Group AGTRIM1,624,415$29.2M
NORTHERN TRUST CORPADD1,210,732$21.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

31 analysts
Hold 39% rate it Buy or better
Strong Buy7Buy5Hold13Sell5Strong Sell1
12-month targets · 22 analysts

Price is inside the target range. Median implies +32%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 8, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATESell
Sep 30, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Sep 28, 2026Needham
REITERATE
REITERATEUnderperform
Jul 9, 2026Piper Sandler
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$123.2K
sold · 1 insider
DateInsiderTypeValue
Sep 4, 2026
Rodino-Klapac Louise
President, R&D and Tech Ops
Sep 4, 2026
TAX W/H$476.0K
Sep 4, 2026
Rothfuss Cristin
EVP, General Counsel
Sep 4, 2026
TAX W/H$489.4K
Sep 4, 2026
Estepan Ian Michael
Chief Operating Officer
Sep 4, 2026
TAX W/H$551.0K
Sep 4, 2026
Wong Ryan Ho-Yan
Chief Financial Officer
Sep 4, 2026
TAX W/H$294.9K
Jul 28, 2026
SEVERINO MICHAEL
Chief Executive Officer
Jul 28, 2026
AWARD756,104 sh
Jul 28, 2026
SEVERINO MICHAEL
Chief Executive Officer
Jul 28, 2026
AWARD2,224,342 sh
Jun 4, 2026
Chambers Michael Andrew
Director
Jun 4, 2026
AWARD16,875 sh
Jun 4, 2026
Barry Richard
Director
Jun 4, 2026
AWARD16,875 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

24 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
19,297,522
shares short
-13.6%
vs prior settlement
7.8
days to cover
≈18.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
AQR Capital Management LLC filed an amended Schedule 13G disclosing a 1.31% passive stake in Sarepta Therapeutics as…
SC 13G/A · Impact 3/10
Nov 10, 2026 SEC
State Street Corp filed a new Schedule 13G disclosing a 7.4% passive stake in Sarepta Therapeutics as of September 30…
SC 13G · Impact 3/10
Nov 10, 2026 Clinical trial readout
Results Pending: Eteplirsen (Phase 3), completed 64d ago
Trial: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duche
Nov 5, 2026 SEC
The company raised the low end of full-year net product revenue guidance by $50M to $1.25B-$1.3B and lowered the high…
8-K · Impact 5/10
Sep 4, 2026 Insider
Rodino-Klapac Louise surrendered for taxes 21,423 shares
President, R&D and Tech Ops @ $22.22 ($476.0K)
Sep 4, 2026 Insider
Rothfuss Cristin surrendered for taxes 22,025 shares
EVP, General Counsel @ $22.22 ($489.4K)
Sep 4, 2026 Insider
Estepan Ian Michael surrendered for taxes 24,799 shares
Chief Operating Officer @ $22.22 ($551.0K)
Aug 12, 2026 Event
ELEVIDYS
WARNING: ACUTE SERIOUS LIVER INJURY AND ACUTE LIVER FAILURE Acute serious liver injury, including li
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent

SecBot reports

9 filings · 0 bullish · 0 bearish · 2 mixed · 7 neutral
All SRPT filing & press-release reports (9)